# US 2014/0348963 A1 · Pharmaceutical platform technology for the development of natural products

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2014/0348963 A1
- Document ID: US20140348963A1
- Status: Published application
- Kind: A1
- Application number: 14/327,529
- Filed: 2014-07-09
- Published: 2014-11-27
- Earliest claimed: 2007-03-30
- Assignees: Sinoveda Canada, Inc.
- Applicants: Sinoveda Canada Inc.
- Inventors: Yun Kau Tam; Jack Adam Tuszynski
- Web page: https://patentgrep.com/patent/US20140348963A1

## CPC

- G16C 20/30: Prediction of properties of chemical compounds, compositions or mixtures
- A61K 36/48: Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- G06F 18/211: Selection of the most significant subset of features
- G16B 5/00: ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
- G16B 35/00: ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
- G16C 20/60: In silico combinatorial chemistry
- G16C 20/64: Screening of libraries
- G16C: COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G06F: ELECTRIC DIGITAL DATA PROCESSING (computer systems based on specific computational models G06N)
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY

## Abstract

The present invention provides a set of in vitro and in silico methodologies for predicting in vivo pharmacokinetics and pharmacodynamics of multiple components; the methodologies comprise mathematical models for solving multiple unknowns which are linearly independent and/or interacting with each other. The present invention can be applied to develop phytomedicines which contain multiple active ingredients without prior identification, isolation and purification of these components.

## Claims

### Claim at position 1

1-22. (canceled)

### Claim 23

A method of preparing a composition comprising multiple components for drug formulations, wherein the identities of or interactions among the components are not known a priori, the method comprises the steps of:
a) preparing multiple samples of a mixture, said mixture comprises the same multiple components at different concentrations, wherein the identities of or interactions among the components are not known a priori;
b) using in vitro assays or in silico methods to obtain parameters describing the rate of elimination of said components and their active metabolites in a plurality of mammalian tissue systems;
c) using in vitro assays or in silico methods to obtain parameters describing distribution of said components and their active metabolites in a plurality of mammalian tissue systems;
d) obtaining pharmacodynamic parameters describing the response of said samples of mixture;
e) performing Subset-Selection Principal Component Analysis to reduce dimensionality of the parameters from (b) to (d), thereby generating parameters for active components in the mixture;
f) inputting the parameters for active components from (e) into a first computer-based modeling system to estimate optimal weights of the active components, said modeling system comprises
r
≈
r
_
+
∑
i

w
i

(
d
i
-
d
_
i
)
+
∑
i

w
i
′

(
d
i
-
d
_
i
)
2
+
∑
i
,
j

w
i
,
j

(
d
i
-
d
_
i
)

(
d
j
-
d
_
j
)

min
w
i
,
w
i
′
,
w
i
,
j

{
r
-
[
r
_
+
∑
i

w
i

(
d
i
-
d
_
i
)
+
∑
i

w
i
′

(
d
i
-
d
_
i
)
2
+
∑
i
,
j

w
i
,
j

(
d
i
-
d
_
i
)

(
d
j
-
d
_
j
)
]
}
2
wherein r is linearized response, r is average linearized response; wi is weight of the ith component, w′i is weight of the non-linear self-interaction behavior of the ith component, di is the dose of the ith component, di and dj are average doses of the ith and jth component, and wi,j is the weight of the interacting pair,
min
w
i
,
w
i
′
,
w
i
,
j
is a minimization procedure to minimize the difference between r and said first modeling system by varying wi, w′i, wi,j,
wherein said first modeling system generates outputs comprising (i) optimal weights αi and βi,j, which are optimal values of wi and w′i and wi,j obtained from said minimization procedure, and (ii) total dose of the components D, which is defined as Σi=1ndi;
g) inputting the optimal weights, αi and βi,j, from (f) into a second computer-based modeling system that comprises
A
=
α
0
+
∑
i
=
1
n

α
i

x
i
+
∑
i
=
1
n

∑
j
=
1
n

β
i
,
j

x
i

x
j


max
x


α
0
+
∑
i
=
1
n

α
i

x
i
+
∑
i
=
1
n

∑
j
=
1
n

β
i
,
j

x
i

x
j

s
.
t
.


∑
i
=
1
n

x
i
=
1

x
i
≥
0
,
∀
i
wherein, A is estimated response generated by said active components per total dose, α0 is an average linearized response per total dose, xi and xj are defined as d′i/D and d′j/D respectively, which are fractions of said total dose D contributed by the ith and jth component respectively, and wherein
D
=
∑
i
=
1
n

d
i
′
,

max
x
is a maximization procedure achieved by varying xi, ∀i is for all i values,
wherein said second modeling system generates outputs comprising dosages of active components that generate maximal response; and
h) using dosages of active components that generate the maximal response from (g) to prepare a composition comprising multiple components, wherein the dosages for said multiple components are obtained from said dosages of active components that generate the maximal response.

### Claim 24 (depends on 23)

The method of claim 23, wherein the pharmacodynamic parameters describing the response of an individual component are determined through receptor binding assays, enzymatic assays, biochemical response assays, or assays with isolated tissues or organs.

### Claim 25 (depends on 23)

The method of claim 23, wherein said outputs of the first and second computer-based modeling systems comprise pharmacokinetic concentration-time profiles and response-time profiles for the components, or comprise pharmacodynamic descriptions on the synergism or inhibition among the components.

### Claim 26 (depends on 23)

The method of claim 23, wherein the mammalian tissue systems are selected from the group consisting of gastrointestinal tract, liver, kidney, blood, mammary gland, uterus, prostate, brain, and bone.

### Claim 27 (depends on 23)

The method of claim 23, wherein the rate of elimination comprises one or more parameters selected from the group consisting of rate of metabolism, rate of absorption, and rate of degradation.

### Claim 28 (depends on 27)

The method of claim 27, wherein the rate of absorption is determined by rate of permeability measured using cultured cells or intestinal tissues.

### Claim 29 (depends on 26)

The method of claim 26, wherein determining the rate of elimination in gastrointestinal tract comprises assays using artificial gastric or intestinal juice, intestinal flora or intestinal microsomes.

### Claim 30 (depends on 23)

The method of claim 23, wherein the mixture is from botanical or animal sources.
